Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Leukemia 7Lymphoma, Follicular 6Leukemia, B-Cell 6Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Leukemia, Hairy Cell 4Lymphoma 3Lymphoma, Mantle-Cell 2Bronchiolitis Obliterans Syndrome 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Recurrence 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphatic Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Hereditary Sensory and Autonomic Neuropathies 1Heart Failure 1Disease 1Chromosome 17 deletion 1Anemia 1

Interventions

venetoclax 1obinutuzumab 1liposomal doxorubicin 1duvelisib 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1CA-4948 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × obinutuzumab × Other hematologic neoplasm × Clear all
NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡